226 related articles for article (PubMed ID: 18086757)
21. Menopausal hormone therapy and mortality among endometrial cancer patients in the NIH-AARP Diet and Health Study.
Felix AS; Arem H; Trabert B; Gierach GL; Park Y; Pfeiffer RM; Brinton LA
Cancer Causes Control; 2015 Aug; 26(8):1055-63. PubMed ID: 25962764
[TBL] [Abstract][Full Text] [Related]
22. Stopping menopausal hormone therapy: if breast cancer really decreased, why did colorectal cancer not increase?
Nahum GG; Stanislaw H; Simon JA
Maturitas; 2012 Apr; 71(4):354-9. PubMed ID: 22300685
[TBL] [Abstract][Full Text] [Related]
23. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer.
Lin KJ; Cheung WY; Lai JY; Giovannucci EL
Int J Cancer; 2012 Jan; 130(2):419-30. PubMed ID: 21365647
[TBL] [Abstract][Full Text] [Related]
24. Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen.
Hildebrand JS; Gapstur SM; Feigelson HS; Teras LR; Thun MJ; Patel AV
Int J Cancer; 2010 Dec; 127(12):2928-35. PubMed ID: 21351271
[TBL] [Abstract][Full Text] [Related]
25. Long-term survival of nonlocalized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis: The extreme study.
Baandrup L; Galanakis M; Hannibal CG; Dehlendorff C; Hertzum-Larsen R; Mørch LS; Kjaer SK
Int J Cancer; 2022 Nov; 151(9):1512-1522. PubMed ID: 35716136
[TBL] [Abstract][Full Text] [Related]
26. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: part 3. The Women's Health Initiative: unopposed estrogen.
Shapiro S; Farmer RD; Mueck AO; Seaman H; Stevenson JC
J Fam Plann Reprod Health Care; 2011 Oct; 37(4):225-30. PubMed ID: 21642263
[TBL] [Abstract][Full Text] [Related]
27. Menopausal hormone therapy.
Bhavnani BR; Strickler RC
J Obstet Gynaecol Can; 2005 Feb; 27(2):137-62. PubMed ID: 15937590
[TBL] [Abstract][Full Text] [Related]
28. Reproductive factors, menopausal hormone therapies and primary liver cancer risk: a systematic review and dose-response meta-analysis of observational studies.
Zhong GC; Liu Y; Chen N; Hao FB; Wang K; Cheng JH; Gong JP; Ding X
Hum Reprod Update; 2016 Dec; 23(1):126-138. PubMed ID: 27655589
[TBL] [Abstract][Full Text] [Related]
29. Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy - a nationwide study.
Koskela-Niska V; Lyytinen H; Riska A; Pukkala E; Ylikorkala O
Climacteric; 2013 Feb; 16(1):48-53. PubMed ID: 22640598
[TBL] [Abstract][Full Text] [Related]
30. Continuous combined hormone replacement therapy and risk of endometrial cancer.
Hill DA; Weiss NS; Beresford SA; Voigt LF; Daling JR; Stanford JL; Self S
Am J Obstet Gynecol; 2000 Dec; 183(6):1456-61. PubMed ID: 11120510
[TBL] [Abstract][Full Text] [Related]
31. Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis.
Benson VS; Kirichek O; Beral V; Green J
Int J Cancer; 2015 May; 136(10):2369-77. PubMed ID: 25335165
[TBL] [Abstract][Full Text] [Related]
32. Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study.
Du Y; Scheidt-Nave C; Schaffrath Rosario A; Ellert U; Dören M; Knopf H
Climacteric; 2009 Aug; 12(4):329-40. PubMed ID: 19437194
[TBL] [Abstract][Full Text] [Related]
33. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy.
Chubak J; Doherty JA; Cushing-Haugen KL; Voigt LF; Saltzman BS; Hill DA; Beresford SA; Weiss NS
Cancer Causes Control; 2007 Nov; 18(9):1001-7. PubMed ID: 17653829
[TBL] [Abstract][Full Text] [Related]
34. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
[TBL] [Abstract][Full Text] [Related]
35. Hormone therapy and ovarian cancer.
Mørch LS; Løkkegaard E; Andreasen AH; Krüger-Kjaer S; Lidegaard O
JAMA; 2009 Jul; 302(3):298-305. PubMed ID: 19602689
[TBL] [Abstract][Full Text] [Related]
36. Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women's Health Initiative Observational Study.
Trabert B; Coburn SB; Falk RT; Manson JE; Brinton LA; Gass ML; Kuller LH; Rohan TE; Pfeiffer RM; Qi L; Stefanick ML; Wentzensen N; Anderson GL; Xu X
Cancer Causes Control; 2019 Nov; 30(11):1201-1211. PubMed ID: 31542834
[TBL] [Abstract][Full Text] [Related]
37. [Hormone replacement therapy in menopause and risk of breast cancer].
Clavel-Chapelon F; Hill C
Presse Med; 2000 Oct; 29(31):1688-93. PubMed ID: 11094609
[TBL] [Abstract][Full Text] [Related]
38. Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States).
Green PK; Weiss NS; McKnight B; Voigt LF; Beresford SA
Cancer Causes Control; 1996 Nov; 7(6):575-80. PubMed ID: 8932917
[TBL] [Abstract][Full Text] [Related]
39. The Association Between Talc Use and Ovarian Cancer: A Retrospective Case-Control Study in Two US States.
Cramer DW; Vitonis AF; Terry KL; Welch WR; Titus LJ
Epidemiology; 2016 May; 27(3):334-46. PubMed ID: 26689397
[TBL] [Abstract][Full Text] [Related]
40. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration.
Bergendal A; Kieler H; Sundström A; Hirschberg AL; Kocoska-Maras L
Menopause; 2016 Jun; 23(6):593-9. PubMed ID: 27023862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
